MSA Drug Repurposing Review Highlighted Ubiquinol and Exenatide Signals
TL;DR: A 2026 review in Translational Neurodegeneration found that most repurposed multiple system atrophy drugs failed to show disease-slowing effects in trials, while ubiquinol produced the clearest placebo-controlled motor-progression signal. Key Findings No proven disease-modifying therapy: Multiple system atrophy remains a rapidly progressive neurodegenerative disease without an approved treatment that slows progression. Four target classes …
